Manhattan Scientifics Inc (MHTX)

[ssc]

What we have seems obvious, at least to me. The current price reflects the statements from the ceo regarding $3 - $4 million/year from CRS for 2015-2017. With the number of shares o/s, that equates to less than .01/share. After expenses and with a generous p/e applied you get the current share price of .07 to .10. The market is giving absolutely zero value to the Flynn technology because there is absolutely no proof that it works commercially. If/when the machine is delivered to MDA and if /when it is proven to work as advertised for the last 4 years, and if/when management is capable of successfully taking it to market, the stock price could easily reach .30 or higher.

In the hands of this management team, the market, up to now, is not willing to bet on a favorable outcome. Big question is will management be able to produce. Their track record has earned little credibility and that too is reflected in the stock.